Kline Ashley Hartmann 4

What Happened Ashley Kline Hartmann, Chief Commercial Officer of Palvella Therapeutics, received a derivative award covering 38,517 shares on Feb 5, 2026. The Form 4 reports the acquisition at $0.00 (i.e., no cash paid on grant as reported). This is an equity award/option grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-05; Form 4 filed 2026-02-09 (filed within the standard two business days).
• Award: 38,517 derivative shares reported as acquired at $0.00.
• Vesting: Shares subject to an option that vests in equal monthly installments over 48 months beginning Feb 5, 2026, subject to continued service (footnote).
• Shares owned after transaction: Not specified in the provided filing details.
• Transaction type: Award/option grant (code A); not an immediate exercise or sale.

Context This is a standard executive equity grant intended to align long-term incentives; the award vests over four years rather than being immediately exercisable. Because it is a grant (not a purchase or sale), it should be viewed as compensation structure rather than a direct bullish or bearish signal.